Speaker: Bruce Mcmanus, MD, PhD Host: Kevin Janes
MR5, Room 3005
Affiliation: Professor, Pathology and Laboratory Medicine, University of British Columbia
Acute immune rejection of human heart allografts negatively impacts both the patient-recipient and the graft itself. Traditional monitoring for acute rejection requires serial heart biopsies during the first year post-transplant. We and others have been driven to identify a much less invasive, blood-basedmeans by which to monitor for acute rejection in order to augment patient experience and well-being, reduce costs, and assure the absence of damaging rejection in the transplanted heart. This is the story of a developmental process for an omics-based, computationally enabled approach to less invasive, high-value diagnostics.